Edwards Lifesciences upgraded

|About: Edwards Lifesciences Corp (EW)|By:, SA News Editor

Wells Fargo upgrades Edwards Lifesciences (EW) to Outperform with a price target of $82 - $83, up from $67 - $69.

Catalysts for the upgrade include new transcatheter mitral valve implants that will boost 2016 revenue, an improved outlook for Sapien XT and upside potential from litigation with Medtronic (MDT) due to its infringement of two EW US patents.

EW closed Friday at $72.07.